Literature DB >> 18662837

Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies.

Abdurrahman Kadayifci1, Vivian Tan, Philip C Ursell, Raphael B Merriman, Nathan M Bass.   

Abstract

BACKGROUND/AIMS: The precise prevalence of risk factors for atherosclerosis in NASH-related cirrhosis is unknown. The aims of this study were: (1) to compare the prevalence of major risk factors for atherosclerosis between subjects who underwent liver transplantation for NASH-related cirrhosis and those with cirrhosis of other aetiologies and (2) to compare pathologic changes of atherosclerosis within the explants hepatic hilar arteries between the groups.
METHODS: Sixty subjects with NASH-related cirrhosis and 60 subjects with cirrhosis of other aetiologies were reviewed retrospectively. Demographic and clinical characteristics related to atherosclerosis were analyzed and compared. The hepatic hilar arteries of the explanted livers were examined for pathologic changes.
RESULTS: The prevalence of all coronary artery disease (CAD) risk factors and the metabolic syndrome was significantly higher in NASH-related cirrhosis group compared to cirrhosis of other aetiologies. The proportion of patients with a diagnosis of CAD was also significantly higher in the NASH-related cirrhosis group (21.6% vs. 5%, p=0.005). Pathological examination of hilar arteries showed possible atherosclerotic changes in only 4 cases (3 NASH-related cirrhosis; 1 HCV).
CONCLUSIONS: Major risk factors for atherosclerosis are significantly more prevalent in subjects with NASH-related cirrhosis than in subjects with cirrhosis of other aetiologies and are predictive of an increased prevalence of CAD. This study suggests that NASH-related cirrhosis is not protective against atherosclerosis.

Entities:  

Mesh:

Year:  2008        PMID: 18662837     DOI: 10.1016/j.jhep.2008.05.024

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  33 in total

Review 1.  Non-alcoholic fatty liver disease - the heart of the matter.

Authors:  Haneen Azzam; Stephen Malnick
Journal:  World J Hepatol       Date:  2015-06-08

Review 2.  Liver disease, coagulopathies and transfusion therapy.

Authors:  Pier Mannuccio Mannucci; Armando Tripodi
Journal:  Blood Transfus       Date:  2012-09-12       Impact factor: 3.443

Review 3.  Role of cardiovascular intervention as a bridge to liver transplantation.

Authors:  Zankhana Raval; Matthew E Harinstein; James D Flaherty
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 4.  Cardiac imaging for the assessment of patients being evaluated for kidney or liver transplantation.

Authors:  Kalindi Parikh; Andrew Appis; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2014-10-08       Impact factor: 5.952

Review 5.  Preventive Strategies for Nonalcoholic Fatty Liver Disease After Liver Transplantation.

Authors:  Narendra S Choudhary; Sanjiv Saigal
Journal:  J Clin Exp Hepatol       Date:  2019-05-30

6.  Pronounced Coronary Arteriosclerosis in Cirrhosis: Influence on Cardiac Function and Survival?

Authors:  Karen V Danielsen; Signe Wiese; Jens Hove; Flemming Bendtsen; Søren Møller
Journal:  Dig Dis Sci       Date:  2018-03-08       Impact factor: 3.199

Review 7.  Statin therapy in patients with cirrhosis.

Authors:  Andrew P Wright; Srinath Adusumalli; Kathleen E Corey
Journal:  Frontline Gastroenterol       Date:  2014-08-08

Review 8.  Treatment of Dyslipidemia in Common Liver Diseases.

Authors:  Elizabeth K Speliotes; Maya Balakrishnan; Lawrence S Friedman; Kathleen E Corey
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-21       Impact factor: 11.382

Review 9.  Arrhythmia risk in liver cirrhosis.

Authors:  Ioana Mozos
Journal:  World J Hepatol       Date:  2015-04-08

Review 10.  Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?

Authors:  Narendra S Choudhary; Ajay Duseja
Journal:  J Clin Exp Hepatol       Date:  2019-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.